|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☒
|
Definitive Proxy Statement
|
|
☐
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material Under Rule 14a-12
|
|
|
|
|
|
☒
|
|
No fee required.
|
||
|
|
|||
☐
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
||
|
|
1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
5)
|
|
Total fee paid:
|
|
|
|||
☐
|
|
Fee paid previously with preliminary materials.
|
||
|
|
|||
☐
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
|
||
|
|
1)
|
|
Amount Previously Paid:
|
|
|
2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
3)
|
|
Filing Party:
|
|
|
4)
|
|
Date Filed:
|
1. |
elect the nine director nominees listed in the accompanying proxy statement;
|
2. |
ratify the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for 2021;
|
3. |
approve, in a non-binding, advisory vote, the compensation paid to our named executive officers; and
|
4. |
transact any other business that may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
☐
|
This Proxy Statement and 2020 Annual Report to Stockholders, which includes the Annual Report on Form 10-K for the year ended December 31, 2020 are available at http://materials.proxyvote.com/686688.
|
By order of the Board of Directors,
|
![]() Isaac Angel
Chairman of the Board
|
1
|
|
1
|
|
6
|
|
9
|
|
9
|
|
9 |
|
10 |
|
10 |
|
10 |
|
14 |
|
14 |
|
15 |
|
15 |
|
15 |
|
16 |
|
18 |
|
19 |
|
20 |
|
PROPOSAL 3 - ADVISORY VOTE ON EXECUTIVE COMPENSATION | 22 |
23 |
|
33 |
|
34 |
|
34 |
|
36 |
|
41 |
|
43 |
|
43 |
|
44 |
|
46 |
|
48 |
|
51 |
|
52 |
|
53 |
|
53 |
(i) |
vote to elect the nine director nominees listed herein;
|
(ii) |
vote to ratify the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (“PwC”) as our independent registered public accounting firm for 2021;
|
(iii) |
vote to approve, in a non-binding, advisory vote, the compensation of our named executive officers (“NEOs”); and
|
(iv) |
transact any other business that may properly come before the Annual Meeting.
|
• |
By Internet - You may submit your proxy by going to www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You will need the Notice or proxy card in order to vote by Internet.
|
• |
By Telephone - You may submit your proxy by using a touch-tone telephone to call toll-free 1-800-776-9437 in the United States or 1-718-921-8500 from foreign countries and following the instructions. You will need the Notice or proxy
card in order to vote by telephone.
|
• |
By Mail - You may vote by mail by requesting a proxy card from us, indicating your vote by completing, signing and dating the card where indicated and by mailing or otherwise returning the card in the envelope that will be provided to
you. You should sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity, indicate your name and title or capacity.
|
• |
Proposal 1: elect the nine director nominees listed in this Proxy Statement (the “Nominee Proposal”);
|
• |
Proposal 2: ratify the appointment of PwC as our independent registered public accounting firm for 2021 (the “Ratification Proposal”); and
|
• |
Proposal 3: approve the compensation of our NEOs on an advisory basis (the “Say-on-Pay Proposal”).
|
● |
by signing and delivering another proxy with a later date that is received no later than May 4, 2021;
|
● |
by voting again by Internet or telephone at a later time before the closing of those voting facilities at 11:59 p.m. (Eastern Daylight Time) on May 4, 2021;
|
● |
by sending a written statement to that effect to the Company’s Corporate Secretary, provided that such statement is received no later than May 4, 2021; or
|
● |
by voting via the Internet at the Annual Meeting.
|
Proposal
|
|
Vote Required
|
|
Voting Options
|
|
Board
Recommendation(1) |
|
Broker
Discretionary Voting Allowed |
|
Impact of
Abstain Vote |
Proposal 1 –
Nominee Proposal |
Majority of votes cast – "FOR" must exceed "AGAINST" votes
|
"FOR"
"AGAINST" "ABSTAIN" |
"FOR"
|
No
|
None
|
|||||
Proposal 2 –
Ratification Proposal |
Majority of votes present in person or represented by proxy and entitled to vote on this item of business
|
"FOR"
"AGAINST" "ABSTAIN" |
"FOR"
|
Yes
|
"AGAINST"
|
|||||
Proposal 3 –
Say-on-Pay Proposal |
|
Majority of votes present in person or represented by proxy and entitled to vote on this item of business
|
|
"FOR"
"AGAINST" "ABSTAIN" |
|
"FOR"
|
|
No
|
|
"AGAINST"
|
(1)
|
If you are a registered holder and you sign and submit your proxy card without indicating your voting instructions, your shares will be voted in accordance with the Board’s recommendation.
|
|
Audit
Committee
|
Compensation
Committee
|
Nominating and
Corporate Governance
Committee |
Investment
Committee |
Isaac Angel
Chairman
|
||||
Ravit Barniv*(4)
|
X
|
X, Chair
|
X
|
|
Dan Falk*
Lead Independent Director
|
X, Chair
|
X
|
||
Albertus “Bert” Bruggink*
|
X(3)
|
|||
David Granot*
|
X
|
X
|
X, Chair
|
|
Stan H. Koyanagi*
|
X(1)
|
|||
Hidatake Takahashi*
|
X(2)
|
|||
Dafna Sharir*
|
X
|
X
|
||
Stanley B. Stern*
|
X
|
X, Chair
|
||
Byron G. Wong*
|
X
|
(1) |
Appointed to serve on the Compensation Committee in accordance with the terms of the Governance Agreement.
|
(2) |
Appointed to serve on the Nominating and Corporate Governance Committee in accordance with the terms of the Governance Agreement.
|
(3) |
Appointed to serve on the Investment Committee in accordance with the terms of the Governance Agreement.
|
(4) |
Ms. Barniv has notified us that she will not stand for reelection at the Annual Meeting, leaving the Board effective at the conclusion of the Annual Meeting.
|
• |
making recommendations to our Board as to changes in Ormat’s general compensation philosophy;
|
• |
making recommendations to our Board with respect to the adoption, amendment, termination or replacement of incentive compensation, equity-based plans, revenue sharing plans or other compensation plans maintained by the Company;
|
• |
making recommendations to our Board as to the appropriate compensation for Board members; and
|
• |
monitoring Ormat’s compliance with SEC rules and regulations regarding stockholder approval of certain executive compensation.
|
• |
provided additional disclosure in its Sustainability Report regarding management and employee diversity;
|
• |
adjusted compensation practices for executive officers; and
|
• |
enhanced its “Compensation Discussion and Analysis” disclosure.
|
2020 ($)
|
2019 ($)
|
|||||||
Audit Fees(1)
|
3,395,880
|
4,904,430
|
||||||
Audit-Related Fees(2)
|
341,996
|
107,960
|
||||||
Tax Fees(3)
|
1,950,908
|
1,757,328
|
||||||
All Other Fees(4)
|
3,870
|
3,870
|
||||||
Total:
|
5,692,654
|
6,773,588
|
(1) |
Audit Fees represent the aggregate fees billed for the audits of the annual financial statements and the Company’s internal control over financial reporting; for review of the financial statements included in the Company’s Form 10-Q
filings; for the audits and reviews of certain of our subsidiaries; and for services that are normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings. Audit fees for the
year ended 2020 decreased compared to 2019 mainly due to a decrease in the work related to the Company’s remediation plan due to the progress in developing and implementing the remediation plan..
|
(2) |
Audit-Related Fees represent the aggregate fees billed for services related to the performance of the audit or review of our financial statements and that are not reported under paragraph (1) above, due diligence related to mergers and
acquisitions and consulting on financial accounting/reporting standards.
|
(3) |
Tax Fees represent the aggregate fees billed for international tax compliance, tax advice, and tax planning services.
|
(4) |
All Other Fees represent annual software license fees.
|
|
Dan Falk, Chair
Ravit Barniv David Granot
Stanley B. Stern
Byron G. Wong
|
Name
|
Age
|
Position
|
Isaac Angel
|
64
|
Chairman of the Board, Former Chief Executive Officer
|
Doron Blachar
|
54
|
Chief Executive Officer
|
Assaf Ginzburg
|
45
|
Chief Financial Officer
|
Shlomi Argas
|
56
|
President and Head of Operations and Products
|
Ofer Benyosef
|
57
|
Executive Vice President—Energy Storage and Business Development
|
Zvi Krieger
|
65
|
Executive Vice President—Electricity Segment
|
Shimon Hatzir
|
59
|
General Manager, Energy Storage and Solutions Segment (On April 1, 2021, Mr. Hatzir will be the Company’s Executive Vice President—Electricity Segment)
|
BENEFICIAL OWNERS OF MORE THAN 5%
|
AMOUNT AND NATURE OF BENEFICIAL OWNERSHIP
|
PERCENT OF COMMON STOCK OUTSTANDING
|
||||||
ORIX CORPORATION
|
10,988,577
|
(1)
|
19.6
|
%
|
||||
BLACKROCK, INC.
|
7,077,497
|
(2)
|
12.6
|
%
|
||||
MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD.
|
4,296,323
|
(3)
|
7.7
|
%
|
||||
THE VANGUARD GROUP
|
4,233,322
|
(4)
|
7.6
|
%
|
||||
CLAL INSURANCE ENTERPRISES HOLDINGS LTD.
|
3,235,562
|
(5)
|
5.8
|
%
|
||||
DIRECTORS, DIRECTOR NOMINEES AND NAMED EXECUTIVE OFFICERS
|
||||||||
ISAAC ANGEL††
|
340,847
|
(6)
|
*
|
|||||
RAVIT BARNIV††
|
7,115
|
(7)
|
*
|
|||||
ALBERTUS BRUGGINK††
|
−
|
−
|
||||||
DAVID GRANOT††
|
6,356
|
(8)
|
*
|
|||||
DAN FALK††
|
7,115
|
(9)
|
*
|
|||||
STAN H. KOYANAGI††
|
10,331
|
(10)
|
*
|
|||||
MIKE NIKKEL††
|
-
|
-
|
||||||
DAFNA SHARIR††
|
6,202
|
(11)
|
*
|
|||||
HIDETAKE TAKAHASHI††
|
-
|
-
|
||||||
STANLEY B. STERN††
|
23,799
|
(12)
|
*
|
|||||
BYRON G. WONG††
|
11,952
|
(13)
|
*
|
|||||
DORON BLACHAR†
|
100,943
|
(14)
|
*
|
|||||
ASSAF GINZBURG†
|
20,000
|
*
|
||||||
HEZI KATTAN†
|
15,201
|
(15)
|
*
|
|||||
ZVI KRIEGER†
|
33,894
|
(16)
|
*
|
|||||
SHLOMI ARGAS†
|
30,894
|
(17)
|
*
|
|||||
OFER BENYOSEF†
|
511
|
*
|
||||||
DIRECTORS AND EXECUTIVE OFFICERS AS A GROUP (15 PERSONS)
|
599,959
|
(18)
|
1.1
|
%
|
(1) |
Based on Schedule 13D/A (Amendment No. 2) filed with the SEC on November 27, 2020 by ORIX. ORIX’s address is Hamamatsucho Building, 1-1-1 Shibaura, Minato-ku, Tokyo 105-0023, Japan.
|
(2) |
Based on Schedule 13G/A (Amendment No. 3) filed with the SEC on January 27, 2021 by BlackRock Inc. (“Blackrock”). Includes, as of December 31, 2019, 7,077,497 shares beneficially owned, consisting of 6,997,752 shares as to which
BlackRock has sole voting power and 7,077,497 shares to which BlackRock has sole dispositive power. BlackRock’s address is 55 East 52nd Street, New York, NY 10055.
|
(3) |
Based on Schedule 13G filed with the SEC on February 16, 2021 by Migdal Insurance & Financial Holdings Ltd. (“Migdal”). Includes, as of December 31, 2020, (i) 4,296,320 Ordinary Shares held for members of the public through, among
others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Reporting Person, each of which subsidiaries operates under independent management and makes independent
voting and investment decisions, and (ii) 382,303 Ordinary Shares held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and
investment decisions, and (iii) 3 beneficially held for their own account (Nostro account). Migdal’s address is 4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel.
|
(4) |
Based on Schedule 13G/A (Amendment No. 5) filed with the SEC on February 10, 2021 by The Vanguard Group (“Vanguard”). Includes, as of December 31, 2019, 4,233,322 shares beneficially owned, consisting of 92,700 as to which Vanguard has
shared voting power, 4,097,516 shares as to which Vanguard has sole dispositive power and 125,806 shares as to which Vanguard has shared dispositive power. Vanguard’s address is 100 Vanguard Blvd., Malvern, PA 19355.
|
(5) |
Based on Schedule 13G/A (Amendment No. 3) filed with the SEC on February 16, 2021 by Clal Insurance Enterprises Holdings Ltd. (“Clal”). Includes, as of December 31, 2019, (i) 3,147,957 shares held for members of the public through, among
others, provident funds and/or pension funds and/or insurance policies, which are managed by subsidiaries of Clal, which subsidiaries operate under independent management and make independent voting and investment decisions and (ii) 87,605
shares beneficially held for Clal’s account. Clal’s address is 36 Raul Walenberg St., Tel Aviv 66180, Israel.
|
(6) |
Includes 312,325 shares of Common Stock underlying stock appreciation rights (“SARs”).
|
(7) |
Includes 4,192 shares of Common Stock underlying SARs.
|
(8) |
Includes 4,192 shares of Common Stock underlying SARs.
|
(9) |
Includes 4,192 shares of Common Stock underlying SARs.
|
(10) |
Includes 7,500 shares of Common Stock underlying options and 2,831 shares of Common Stock underlying SARs.
|
(11) |
Includes 3,603 shares of Common Stock underlying SARs.
|
(12) |
Includes 15,000 shares of Common Stock underlying options and 4,192 shares of Common Stock underlying SARs.
|
(13) |
Includes 7,500 shares of Common Stock underlying options and 2,831 shares of Common Stock underlying SARs.
|
(14) |
Includes 93,689 shares of Common Stock underlying SARs.
|
(15) |
Includes 13,333 shares of Common Stock underlying SARs.
|
(16) |
Includes 28,400 shares of Common Stock underlying SARs.
|
(17) |
Includes 28,400 shares of Common Stock underlying SARs.
|
(18) |
Includes 30,000 shares of Common Stock underlying options and 488,847 shares of Common Stock underlying SARs.
|
• |
the information set forth in the “Compensation Discussion and Analysis” section of this Proxy Statement, which describes our compensation objectives and the various elements of our compensation program and policies applicable to our
named executive officers; and
|
• |
the tables, narrative disclosures and other information set forth in the “Executive Compensation” section of this Proxy Statement, which describes how we have compensated our named executive officers.
|
Isaac Angel
Doron Blachar
Assaf Ginzburg
Zvi Krieger
Shlomi Argas
Hezi Kattan
|
Chairman of the Board, Former Chief Executive Officer
Chief Executive Officer
Chief Financial Officer
Executive Vice President—Electricity Segment
President and Head of Operations and Products
General Counsel
|
1. |
Annual salary, our short-term element of compensation which is paid monthly, is intended to provide a predictable annual income at a level consistent with the individual contributions of our executive officers.
|
2. |
Annual bonuses, our medium-term element of compensation which are paid annually to our executive officers, are intended to link our executive officers’ compensation to the Company’s overall annual performance, as well as, in most cases,
their individual achievements.
|
3. |
Equity awards, our long-term element of compensation, are designed to promote long-term leadership and align the interests of our executive officers with those of our stockholders, while their vesting schedule assists us in retaining our
executive officers.
|
NEO
|
Revenue
|
Adjusted EBITDA
|
Individual Performance Criteria
|
CEO Goals
|
Doron Blachar, Chief Executive Officer and Former Chief Financial Officer
|
21.2%
|
25%
|
28.8%
|
25%
|
Assaf Ginzburg, Chief Financial Officer
|
22.5%
|
30%
|
22.5%
|
25%
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
10%
|
10%
|
55%
|
25%
|
Shlomi Argas, President and Head of Operations and Products
|
17.5%
|
17.5%
|
40%
|
25%
|
Hezi Kattan, General Counsel
|
20%
|
15%
|
40%
|
25%
|
Company Performance Metric
|
Target
|
Actual
|
Revenue
|
742
|
705
|
Adjusted EBITDA
|
415
|
420
|
Company Performance Metric
|
Target
|
Actual
|
Revenue
|
725
|
705
|
Adjusted EBITDA
|
407.5
|
420
|
NEO
|
Revenue
|
Adjusted EBITDA
|
Individual Performance Criteria
|
CEO Goals
|
Doron Blachar, Chief Executive Officer and Former Chief Financial Officer
|
2.3%
|
13.1%
|
23.8%
|
25%
|
Assaf Ginzburg, Chief Financial Officer
|
7.1%
|
24.9%
|
22.5%
|
25%
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
1.2%
|
6.6%
|
28.6%
|
25%
|
Shlomi Argas, President and Head of Operations and Products
|
2.0%
|
11.5%
|
12.2%
|
25%
|
Hezi Kattan, General Counsel
|
2.3%
|
9.8%
|
24.7%
|
25%
|
NEO
|
% of Award Earned Paid Out
|
Doron Blachar, Chief Executive Officer and Former Chief Financial Officer
|
64%
|
Assaf Ginzburg, Chief Financial Officer
|
80%
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
61%
|
Shlomi Argas, President and Head of Operations and Products
|
51%
|
Hezi Kattan, General Counsel
|
62%
|
Three-year relative TSR
|
PSUs earned*
|
75th percentile and above
|
150% (maximum)
|
55th percentile
|
100% (target)
|
35th percentile
|
50% (threshold)
|
Below 35th percentile
|
0%
|
* subject to linear interpolation
|
|
Ravit Barniv, Chair
Dan Falk Dafna Sharir Stan H. Koyanagi |
Name and Principal Position
|
Year
|
Salary ($)
|
Bonus ($)(3)
|
Stock Awards ($)(1)
|
Option Awards ($)(2)
|
Non-Equity Incentive Plan Compensation ($)(3)
|
All Other Compensation ($) (10) (11)
|
Total ($)
|
Isaac Angel, Former Chief Executive Officer
|
2020
|
635,507
|
-
|
-
|
-
|
900,000
|
307,234(4)
|
1,842,741
|
2019
|
611,067
|
–
|
900,000
|
149,620
|
1,660,687
|
|||
2018
|
594,206
|
–
|
2,148,379
|
4,298,022
|
800,000
|
143,944
|
7,984,551
|
|
Doron Blachar, Chief Executive Officer
|
2020
|
437,474
|
750,000
|
750,000
|
355,000
|
113,289(5)
|
2,405,763
|
|
2019
|
388,280
|
–
|
–
|
–
|
253,000
|
105,743
|
747,024
|
|
2018
|
373,424
|
–
|
–
|
–
|
100,000
|
100,348
|
573,772
|
|
Assaf Ginzburg, Chief Financial Officer
|
2020
|
223,979(11)
|
35,000
|
450,000
|
450,000
|
141,000
|
45,214(9)
|
1,345,193
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
2020
|
311,225
|
375,000
|
375,000
|
153,000
|
71,638(6)
|
1,285,863
|
|
2019
|
298,864
|
–
|
–
|
–
|
160,000
|
87,467
|
546,332
|
|
2018
|
286,923
|
–
|
225,017
|
451,311
|
101,000
|
84,365
|
1,148,616
|
|
Shlomi Argas, President and Head of Operations and Products
|
2020
|
301,583
|
13,000
|
375,000
|
375,000
|
123,000
|
104,821(7)
|
1,292,404
|
2019
|
290,247
|
–
|
–
|
–
|
206,000
|
99,051
|
595,297
|
|
2018
|
283,064
|
–
|
225,017
|
451,311
|
154,000
|
92,764
|
1,206,156
|
|
Hezi Kattan,
General Counsel |
2020
|
276,739
|
12,000
|
375,000
|
375,000
|
138,000
|
76,848(8)
|
1,253,587
|
2019
|
258,681 |
–
|
–
|
–
|
168,000
|
72,273
|
498,955 |
(1) |
The dollar amounts represent the aggregate grant date fair value of the applicable equity awards. $375,000, $225,000, $187,500, $187,500 and $187,500 represents the grant date fair value of all RSU awards to each of Messrs. Blachar,
Ginzburg, Krieger, Argas and Kattan, respectively, which are calculated in accordance with the accounting standards for share-based compensation using Ormat’s closing stock price on the next day of business following the date of grant. Each
RSU represents the right to receive one share of Common Stock upon vesting. The “Stock Awards” column above also reflects the $375,000, $225,000, $187,500, $187,500 and $187,500 grant date fair values of the target number of Performance
Stock Units for each of Messrs. Blachar, Ginzburg, Kreiger, Argas and Kattan, respectively, that were eligible to vest based on our relative TSR performance goals, which for accounting purposes is based on the probable outcome (determined
as of the grant date) of the performance-based condition applicable to the grant. Assuming the maximum level of performance achievement for the 2020 Performance Stock Units, which is 150% of target, the aggregate values of Performance
Stock Units for our NEOs in 2020 are $885,647, $416,417, $390,687, $390,687, and $390,687 for each of Messrs. Blachar, Ginzburg, Krieger, Argas and Kattan, respectively.
|
(2) |
Represents the grant date fair value of SARs awards. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised
exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised. The fair value of each grant of stock-based awards on the date of grant is estimated using the Exercise
Multiple-Based Lattice SAR-Pricing Model and the assumptions noted in the following table.
|
Year Ended December 31,
|
||||||||||||
2020
|
2019
|
2018
|
||||||||||
Risk-free interest rates
|
0.4
|
%
|
1.8
|
%
|
2.8
|
%
|
||||||
Expected lives (in years)
|
5.8
|
3.5
|
3.5
|
|||||||||
Dividend yield
|
0.6
|
%
|
0.7
|
%
|
0.9
|
%
|
||||||
Expected volatility
|
28.8
|
%
|
25.1
|
%
|
25.5
|
%
|
||||||
Forfeiture rate
|
8.2
|
%
|
8.6
|
%
|
3.1
|
%
|
(3) |
The “Non-Equity Incentive Plan Compensation” column reflects cash awards for Mr. Angel pursuant to his employment agreement and the amount of any cash awards granted under the Management Plan to other NEOs. Mr. Blachar’s cash award
reflects $103,000 earned pursuant to the Management Plan and $252,000 earned pursuant to the Blachar Annual Cash Bonus Plan. These amounts reflect cash awards earned for 2020 performance which are paid in 2021. The “Bonus” column reflects
the discretionary cash bonus that certain members of management received for their significant contributions in managing the global business through the impact of COVID-19 in 2020. For more information, see “−Determination of Amounts and
Formulas for Compensation-Annual Bonus” above.
|
(4) |
Includes payments of accrued vacation days in connection with his retirement in the amount of $153,000; car-related expenses in the amount of $32,059; Israel National Insurance in the amount of $10,776; U.S. Social Security in the amount
of $9,181; health insurance in the amount of $258; convalescence pay in the amount of $1,835; Education Fund in the amount of $4,111 and perquisites amounting to $1,407.
|
(5) |
Includes payments of car-related expenses in the amount of $25,499; Israel National Insurance in the amount of $10,776; health insurance in the amount of $70; convalescence pay in the amount of $1,835; Education Fund in the amount of
$4,111; and perquisites amounting to $1,745.
|
(6) |
Includes payments of car-related expenses in the amount of $9,803; Israel National Insurance in the amount of $10,420; health insurance in the amount of $72; convalescence pay in the amount of $1,835; Education Fund in the amount of
$4,111; vacation redemption in the amount of $14,893 and perquisites amounting to $1,310.
|
(7) |
Includes payments of car-related expenses in the amount of $23,861; Israel National Insurance in the amount of $10,776; health insurance in the amount of $71; convalescence pay in the amount of $1,835; Education Fund in the amount of
$4,111; and perquisites amounting to $1,347.
|
(8) |
Includes payments of car-related expenses in the amount of $15,872; Israel National Insurance in the amount of $10,776; convalescence pay in the amount of $1,193; Education Fund in the amount of $4,111; and perquisites amounting to
$1,917.
|
(9) |
Includes payments of car-related expenses in the amount of $6,838; Israel National Insurance in the amount of $7,264; Education Fund in the amount of $2,791; and perquisites amounting to $667.
|
(10) |
Amounts in this column also include severance and pension contributions as required by Israeli law. For more information, see “Compensation Discussion and Analysis—Retirement and Other Local Benefits” above.
|
(11) |
Car-related expenses included in this column include also gas, maintenance and insurance, and are provided in amounts that are customary and prevalent among Israeli companies in comparable industries.
|
Name
|
Type of Award
|
Grant Date
|
Estimated Future Payouts
Under Non-Equity Incentive Plan Compensation (1) |
Estimated Future Payouts
Under Equity Incentive Plan Compensation |
All Other Stock Awards: Number of Shares of Stock or Units (#)
|
All Other Option Awards: Number of Securities Underlying Options (#)
|
Exercise or Base Price of Option Awards ($/Sh)
|
Grant Date Fair Value of Stock and Option Awards (2)
|
||||
Threshold ($)
|
Target
($)
|
Maximum
($)
|
Threshold (#)
|
Target
(#)
|
Maximum
(#)
|
|||||||
Isaac Angel
|
Annual Cash Incentive
|
−
|
150,000
|
900,000
|
||||||||
Doron Blachar
|
Annual Cash Incentive: Management Plan
|
−
|
18,000
|
107,000
|
161,000
|
|||||||
Annual Cash Incentive: Blachar Annual Cash Bonus Plan
|
−
|
−
|
−
|
250,000
|
||||||||
PSU
|
7/1/20 (3)
|
3,270
|
6,540
|
9,810
|
||||||||
RSU
|
7/1/20 (4)
|
6,020
|
||||||||||
SAR
|
7/1/20 (5)
|
45,356
|
63.40
|
$750,000
|
||||||||
Assaf Ginzburg
|
Annual Cash Incentive
|
−
|
19,556
|
117,373
|
176,000
|
|||||||
PSU
|
5/12/20 (3)
|
1,538
|
3,075
|
4,613
|
||||||||
RSU
|
5/12/20 (4)
|
3,350
|
||||||||||
SAR
|
5/12/20 (5)
|
25,524
|
68.34
|
$450,000
|
||||||||
Zvi Krieger
|
Annual Cash Incentive
|
−
|
27,778
|
166,667
|
250,000
|
|||||||
PSU
|
6/15/20 (3)
|
1,443
|
2,885
|
4,328
|
||||||||
RSU
|
6/15/20 (4)
|
2,760
|
||||||||||
SAR
|
6/15/20 (5)
|
20,808
|
69.14
|
$375,000
|
||||||||
Shlomi Argas
|
Annual Cash Incentive
|
−
|
26,889
|
161,333
|
242,000
|
|||||||
PSU
|
6/15/20 (3)
|
1,443
|
2,885
|
4,328
|
||||||||
RSU
|
6/15/20 (4)
|
2,760
|
||||||||||
SAR
|
6/15/20 (5)
|
20,808
|
69.14
|
$375,000
|
||||||||
Hezi Kattan
|
Annual Cash Incentive
|
−
|
24,667
|
138,000
|
222,000
|
|||||||
PSU
|
6/15/20 (3)
|
1,443
|
2,885
|
4,328
|
||||||||
RSU
|
6/15/20 (4)
|
2,760
|
||||||||||
SAR
|
6/15/20 (5)
|
20,808
|
69.14
|
$375,000
|
(1) |
Represents the Threshold, Target and Maximum cash payout opportunities for fiscal 2020 under the annual incentive plan. For a further discussion of the payout opportunities, see “Compensation Discussion and Analysis—Determination of
Amounts and Formulas for Compensation-Annual Bonus.”
|
(2)
|
Represents the aggregate grant date fair value, computed pursuant to FASB ASC Topic 718. Please see note 15 in the notes to the Company’s consolidated financial statements in our 2020 Annual Report for a
discussion of the assumptions underlying these calculations.
|
(3)
|
Represents the shares of common stock underlying PSUs granted to certain of our NEOs under our 2018 Plan in 2020. The Performance Stock Units will be earned based on our relative TSR performance over a certain
amount of time. We discuss these awards under the heading “Compensation Discussion and Analysis – Determination of Amounts and Formulas for Compensation– Equity Awards". The amounts disclosed in the "Estimated Future Payouts Under Equity
Incentive Plan Awards" columns represent the number of shares issuable assuming achievement of the specific Threshold, Target or Maximum levels of performance established by the Compensation Committee for these Performance Stock Units over
the performance period.
|
(4)
|
Represents the shares of common stock underlying SARs granted to certain of our NEOs under our 2018 Plan in 2020. We discuss these awards under the heading “Compensation Discussion and
Analysis – Determination of Amounts and Formulas for Compensation– Equity Awards".
|
(5)
|
Represents shares of our common stock underlying RSUs granted under our 2018 Plan in 2020.
|
• |
Salary: Annual gross salary of NIS2,141,000 (equal to approximately $665,941 based on the representative exchange rate set by the Bank of Israel on December 31, 2020), which is linked to the
Israeli consumer price index.
|
• |
Annual Performance Bonus: If the Company’s annual consolidated net income is above $20 million, an annual bonus calculated as follows: 75% of the annual bonus will be based on achievement of
specific performance metrics that measure the financial performance of the Company (the “Financial Performance Bonus”) and 25% of the annual bonus will be determined at the discretion of the Compensation Committee based on the achievement
of other goals, such as diversity, social and environmental responsibility and merger and acquisition activities (the “KPI Bonus”). The Financial Performance Bonus is equal to (a) 0.75% of the Company's annual consolidated net income up to
$50 million (inclusive) and (b) 1.00% of the portion of Company's annual consolidated net income that is above $50 million, if any; provided that the Financial Performance Bonus shall not exceed $675,000. The Annual KPI Bonus shall not
exceed $225,000.
|
• |
Equity grants:
|
o |
The first two grants pursuant to Mr. Angel’s employment agreement accelerated and were sold as part of the transaction with ORIX.
|
o |
Third Grant: 100,000 SARs granted on June 14, 2016 with an exercise price equal to $42.87 per share of Common Stock underlying the SARs, the closing price of our Common Stock on the date of grant,
under the 2012 ICP. The SARs vest in three equal installments on the two, three and four year anniversaries of the date of grant and expire seven years following the date of grant. The vesting period for these SARs was accelerated in
connection with the ORIX Transaction. Please see Note (1) to the “Outstanding Equity Awards at Fiscal Year-End” table below.
|
o |
Fourth Grant: 294,889 SARs granted on May 8, 2018 with an exercise price equal to $55.16 per share of Common Stock underlying the SARs, the closing price of our Common Stock on the date of grant,
and 36,915 RSUs, under the 2018 ICP. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs and SARs will vest 22%, 22%, 28% and 28%, respectively, on the one, two, three and four year anniversaries of
the date of grant (vesting commencement date November 17, 2017).
|
• |
Termination: Each of the Company and Mr. Angel may terminate the employment agreement, for any reason, by providing six months prior notice of such termination (the “Notice Period”). Other than in
the case of termination of employment by the Company for “Cause” (as defined in the employment agreement), Mr. Angel will be entitled to continue to receive his compensation during the Notice Period.
|
• |
Termination in connection with a Change of Control: In the event that Mr. Angel’s employment is terminated by the Company without “Cause”, or he resigns for a “Good Reason” (as defined in the
employment agreement) within two (2) months before, or twelve months following, the consummation of a “Change of Control” (as defined in the Employment Agreement), Mr. Angel is entitled to the following: (i) the Notice Period (and
consequently, the period during which compensation is payable to Mr. Angel) will be extended from six months to twelve months; and (ii) all the stock options and SARs described above will be accelerated and will become fully vested and
exercisable.
|
Option Awards
|
Stock Awards
|
|||||||
Name
|
Number of Securities
Underlying Unexercised Options (#) Exercisable
|
Number of Securities
Underlying Unexercised Options (#) Unexercisable
|
Option
Exercise Price ($)
|
Option Expiration Date
|
Number of
Shares or Units of Stock That Have Not Vested (#) |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(19) |
Equity Incentive Plan Awards: Number of Unearned Shares That Have Not Vested (#)
|
Equity Incentive Plan Awards: Market Value of Unearned Shares That Have Not Vested ($)(19)
|
Isaac Angel
|
100,000(1)
|
42.87
|
June 14, 2022
|
|||||
11,093(2)
|
1,001,476
|
|||||||
212,325
|
82,574(3)
|
55.16
|
November 7, 2023
|
|||||
Doron Blachar
|
42,500(4)
|
42.87
|
June 14, 2022
|
|||||
51,189
|
17,063(5)
|
63.35
|
November 7, 2023
|
|||||
45,356(6)
|
63.40
|
July 1, 2026
|
||||||
2,417(7)
|
218,206
|
|||||||
6,020(8)
|
543,485
|
|||||||
6,540(9)
|
590,431
|
|||||||
Assaf Ginzburg
|
25,524(10)
|
68.34
|
May 12, 2026
|
|||||
3,350(11)
|
302,438
|
|||||||
3,075(12)
|
277,611
|
|||||||
Zvi Krieger
|
10,625(13)
|
42.87
|
June 14, 2022
|
|||||
2,359
|
2,361(5)
|
63.35
|
November 7, 2023
|
|||||
335 (7)
|
30,244
|
|||||||
2,160 (14)
|
195,004
|
|||||||
15,416
|
15,417 (15)
|
53.44
|
June 25, 2024
|
|||||
20,808(16)
|
69.14
|
June 15, 2026
|
||||||
2,760(17)
|
249,173
|
|||||||
2,885(18)
|
260,458
|
|||||||
Shlomi Argas
|
10,625 (13)
|
42.87
|
June 14, 2022
|
|||||
2,359
|
2,361 (5)
|
63.35
|
November 7, 2023
|
|||||
335(7)
|
30,244
|
|||||||
2,160(14)
|
195,005
|
|||||||
15,416
|
15,417(15)
|
53.44
|
June 25, 2024
|
|||||
20,808(16)
|
69.14
|
June 15, 2026
|
||||||
2,760(17)
|
249,173
|
|||||||
2,885(18)
|
260,458
|
|||||||
Hezi Kattan
|
1,868(14)
|
168,644
|
||||||
13,333
|
13,333(15)
|
53.44
|
June 25, 2024
|
|||||
20,808(16)
|
69.14
|
June 15, 2026
|
||||||
2,760(17)
|
249,173
|
|||||||
2,885(18)
|
260,458
|
(1) |
The vesting period for these SARs was accelerated in connection with the ORIX Transaction. As of November 2018, all 100,000 SARs were vested and are exercisable and the Common Stock acquired through the exercise may be sold, transferred
or otherwise disposed.
|
(2) |
Represents RSUs which vested 22% on each of the first and second-year anniversaries of the vesting commencement date (November 7, 2017) and 28% vested or will vest, as applicable on each of the third and the four-year anniversaries of
the November 7, 2017 vesting commencement date. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
(3) |
Represents SARs which vested 22% on each of the first and the second year anniversaries of the vesting commencement date (November 7, 2017) and 28% vested or will vest, as applicable on each of the third and four-year anniversaries of
the November 7, 2017. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the
SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
(4) |
Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by
the number of shares in respect of which the SAR is exercised. As of June 14, 2020, all shares of Common Stock acquired through the exercise of these SARs granted to Mr. Blachar on June 14, 2016 may be sold, transferred or otherwise
disposed.
|
(5) |
Represents SARs which vest 25% on each of the one, two, three and four year anniversaries of the November 7, 2017 grant date. The SARs will become fully exercisable in November 2021. Each SAR represents the right to receive shares of
Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is
exercised.
|
(6) |
Represents SARs which begin to vest two years after the July 1, 2020 grant date, with 50% of the SARs vesting on the second anniversary of the grant date and 25% of the SARs vesting on each of the third and fourth anniversaries of the
grant date. The SARs will become fully exercisable in July 2024. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is
exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
(7) |
Represents RSUs which vest 25% on each of the one, two, three- and four-year anniversaries of the November 7, 2017 grant date. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
(8) |
Represents RSUs which will vest 50% on the second anniversary of the grant date, July 1, 2020, and 25% on each three and four year anniversaries of the grant date. The RSUs will become fully exercisable in July 2024. Each RSU represents
the right to receive one share of Common Stock upon vesting.
|
(9) |
Represents PSUs which will vest 50% on the second anniversary of the grant date, July 1, 2020, and 25% on each three and four year anniversaries of the grant date. The PSUs will become fully exercisable on July 1, 2024. Each PSU
represents the right to receive one share of Common Stock upon vesting.
|
(10) |
Represents SARs which begin to vest two years after the May 12, 2020 grant date, with 50% of the SARs vesting on the second anniversary of the grant date and 25% of the SARs vesting on each of the third and fourth anniversaries of the
grant date. The SARs will become fully exercisable in May 2024. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is
exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
(11) |
Represents RSUs which will vest 50% on the second anniversary of the grant date, May 12, 2020, and 25% on each three and four year anniversaries of the grant date. The RSUs will become fully exercisable on May 12, 2024. Each RSU
represents the right to receive one share of Common Stock upon vesting.
|
(12) |
Represents PSUs which will vest 50% on the second anniversary of the grant date, May 12, 2020, and 25% on each three and four year anniversaries of the grant date. The PSUs will become fully exercisable on May 12, 2024. Each PSU
represents the right to receive one share of Common Stock upon vesting.
|
(13) |
Represents SARs which begin to vest two years after the June 14, 2016 grant date, with 50% of the SARs vesting on the second anniversary of the grant date and 25% of the SARs vesting on each of the third and fourth anniversaries of the
grant date. As of June 14, 2020, all shares of Common Stock acquired through the exercise of these SARs granted on June 14, 2016 may be sold, transferred or otherwise disposed. Each SAR represents the right to receive shares of Common Stock
with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
(14) |
Represents RSUs which vest 50% on the second anniversary of the grant date, June 25, 2018, and 25% on each three and four year anniversaries of the grant date. The RSUs will become fully exercisable in June 2022. Each RSU represents the
right to receive one share of Common Stock upon vesting.
|
(15) |
Represents SARs which vest 50% on the second anniversary of the grant date, June 25, 2018, and 25% on each three- and four-year anniversaries of the June 25, 2018 grant date. The SARs will become fully exercisable in June 2022. Each SAR
represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number
of shares in respect of which the SAR is exercised.
|
(16) |
Represents SARs which will vest 50% on the second anniversary of the grant date, June 15, 2020, and 25% on each three- and four-year anniversaries of the June 15, 2020 grant date. The SARs will become fully exercisable in June 2024. Each
SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the
number of shares in respect of which the SAR is exercised.
|
(17) |
Represents RSUs which will vest 50% on the second anniversary of the grant date, June 15, 2020, and 25% on each three and four year anniversaries of the grant date. The RSUs will become fully exercisable in June 2024. Each RSU
represents the right to receive one share of Common Stock upon vesting.
|
(18) |
Represents PSUs which will vest 50% on the second anniversary of the grant date, June 15, 2020, and 25% on each three and four year anniversaries of the grant date. The PSUs will become fully exercisable in June 2024. Each PSU
represents the right to receive one share of Common Stock upon vesting.
|
(19) |
The market value is based on the closing price of our Common Stock on December 31, 2020 of $90.28, multiplied by the number of units. All amounts shown for PSUs are shown at target level of achievement representing a 100 percent payout.
|
Options Awards
|
Stock Awards
|
|||
Name
|
Number of Shares Acquired on Exercise (#)
|
Value Realized on Exercise ($)
|
Number of Shares Acquired on Vesting (#)
|
Value Realized on Vesting ($)(1)
|
Isaac Angel
|
-
|
-
|
11,092
|
882,480
|
Doron Blachar
|
-
|
-
|
2,418
|
192,376
|
Assaf Ginzburg
|
-
|
-
|
-
|
-
|
Zvi Krieger
|
-
|
-
|
2,494
|
161,335
|
Shlomi Argas
|
-
|
-
|
2,494
|
161,335
|
Hezi Kattan
|
-
|
-
|
1,868
|
116,545
|
Name
|
Termination without Cause ($)
|
Change in Control ($)
|
Doron Blachar
|
566,066
|
4,163,173
|
Assaf Ginzburg
|
78,234
|
78,234
|
Zvi Krieger
|
654,316
|
654,316
|
Shlomi Argas
|
815,697
|
2,622,001
|
Hezi Kattan
|
174,476
|
174,476
|
• |
Base annual retainer of $60,000 as fees related to their service on our Board.
|
• |
Board and committee meeting fees are subject to an aggregate $35,000 cap, regardless of the number of meetings such director attends. The fees include:
|
- |
$2,500 per day for each in-person Board meeting attended; $500 per day for each telephonic Board meeting attended; and $1,000 per day for telephonic participation in an in-person Board meeting.
|
- |
$1,500 per day for each in-person committee meeting attended and $500 per day for each telephonic committee meeting attended.
|
• |
The Chairs of the Audit Committee, Nominating and Corporate Governance Committee, Compensation Committee and Investment Committee receive supplemental annual cash retainers of $15,000, $10,000, $10,000 and $10,000, respectively, none of
which are subject to the $35,000 cap.
|
• |
The non-employee Chairman of the Board receives a supplemental annual retainer with an aggregate value of $100,000, consisting of a $40,000 cash retainer and equity compensation with a value of $60,000, as further described below.
|
• |
We promptly reimburse all directors for transportation and lodging expenses actually incurred to attend meetings of our Board or committees.
|
Name
|
Fee Earned or Paid in Cash ($)
|
Stock Awards($)(1) |
Options Awards ($)(2)
|
Total ($)
|
||||||||||||
Ravit Barniv
|
103,000
|
96,000
|
24,000
|
223,000
|
||||||||||||
Dan Falk
|
108,500
|
96,000
|
24,000
|
228,000
|
||||||||||||
Albertus Bruggink
|
41,000
|
136,000
|
34,000
|
211,000
|
||||||||||||
Todd C. Freeland
|
74,250
|
(4)
|
-
|
-
|
74,250
|
|||||||||||
David Granot
|
102,000
|
96,000
|
24,000
|
222,000
|
||||||||||||
Stan H. Koyanagi
|
-
|
(3)
|
-
|
(3)
|
24,000
|
24,000
|
||||||||||
Yuichi Nishigori
|
-
|
(4)
|
-
|
-
|
-
|
|||||||||||
Hidetake Takahashi
|
-
|
(3)
|
-
|
(3)
|
34,000
|
34,000
|
||||||||||
Dafna Sharir
|
83,500
|
96,000
|
24,000
|
203,500
|
||||||||||||
Stanley B. Stern
|
77,500
|
96,000
|
24,000
|
197,500
|
||||||||||||
Byron Wong
|
77,500
|
96,000
|
24,000
|
197,500
|
(1) |
Represents the grant date fair value of RSU awards based on Ormat’s closing stock price on the next day of business following the date of grant. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
(2) |
Represents the grant date fair value of SARs awards. For a discussion of the assumptions used in reaching this valuation, see footnote 3 to the Summary Compensation Table above.
|
(3) |
Mr. Koyanagi and Mr. Takahashi elected to forego the cash retainer and the RSU awards to which members of our Board are entitled for 2020.
|
(4) |
Mr. Freeland and Mr. Nishigori did not stand for reelection at the annual meeting of the Company in 2020.
|
Name
|
Unexercised Options Outstanding
|
Unexercised SARs Outstanding
|
Unvested RSUs Outstanding
|
|||||||||
Ravit Barniv
|
-
|
5,507
|
1,430
|
|||||||||
Dan Falk
|
-
|
5,507
|
1,430
|
|||||||||
Albertus Bruggink
|
-
|
1,893
|
2,010
|
|||||||||
Todd C. Freeland
|
-
|
-
|
-
|
|||||||||
David Granot
|
-
|
5,507
|
1,430
|
|||||||||
Stan H. Koyanagi
|
7,500
|
4,146
|
-
|
|||||||||
Yuichi Nishigori
|
||||||||||||
Hidetake Takahashi
|
-
|
1,893
|
-
|
|||||||||
Dafna Sharir
|
-
|
4,918
|
1,430
|
|||||||||
Stanley B. Stern
|
15,000
|
5,507
|
1,430
|
|||||||||
Byron Wong
|
7,500
|
4,146
|
1,430
|
• |
beneficially owning, individually or as part of a group, any class or series of voting securities of the Company in excess of 30% of the aggregate amount of the then-outstanding voting securities of such class or series;
|
• |
engaging in any “solicitation” of “proxies” (as those terms are defined under Regulation 14A under the Exchange Act) relating to the election of directors with respect to the Company, becoming a “participant” (as such term is defined
under Regulation 14A under the Exchange Act) in any solicitation seeking to elect directors not nominated by our Board or otherwise seeking to influence any person or group with respect to the voting of any voting securities of the Company
other than with respect to ORIX’s director nominees;
|
• |
voting in favor of or otherwise supporting any transaction that would result in a Change of Control (as defined in the Governance Agreement) of the Company, if the transaction is opposed by our Board;
|
• |
making any public request or proposal seeking to have the Company waive or make amendments to our organizational documents in a manner that would either impede or facilitate a Change of Control of the Company; and
|
• |
making any public request or proposal that the Company effect any material change to its dividend policy.
|
• |
at the time ORIX and its affiliates collectively hold less than 5% of the voting power of all the outstanding voting securities of the Company;
|
• |
upon the mutual written agreement of the Company and ORIX;
|
• |
by ORIX, upon a material breach by the Company of the Governance Agreement that has not been cured within ten business days after written notice thereof has been received by the Company; or
|
• |
by the Company, upon a material breach by ORIX of the Governance Agreement that has not been cured within ten business days after written notice thereof has been received by ORIX.
|
• |
ORIX agreed to take such action as is necessary to procure that at least a majority of the directors designated by ORIX consent to increase the number of directors on Board of Directors to a maximum of ten directors, effective on the
date of the Company’s annual general meeting in 2020; subject to any such expansion solely being made solely for the purpose of the Company’s current CEO, Isaac Angel and no other party, serving on the Board of Directors as an additional
director to those currently serving.
|
• |
The Company agreed to take all such steps as are necessary to ensure that only nine or fewer individuals (inclusive of the directors designated by ORIX) are nominated for approval at its annual general meeting to occur in 2021.
|
• |
The Company agreed that in the event that it has not convened and completed its annual meeting in 2021 on or prior to a date that is 15 months from the date of the Annual Meeting and the number of directors exceeds nine (inclusive of the
directors designated by ORIX), the Chair of the Board of Directors shall at the earliest time practicable convene a special meeting of the Board of Directors to take any and all such action as is necessary to reduce the size of the Board to
no more than nine directors (including the directors designated by ORIX) with immediate effect.
|
|
•
|
|
any related person transaction, and any material amendment or modification to a related person transaction, must be reviewed and approved or ratified by the Audit Committee; provided that a
majority of the members of the Audit Committee are disinterested; and
|
|
•
|
|
any employment relationship or transaction involving an executive officer and any related compensation must be approved by the Compensation Committee of the Board of Directors or
recommended by the Compensation Committee to the Board of Directors for its approval.
|
|
•
|
|
management must disclose to the Audit Committee the name of the related person and the basis on which the person is a related person, the material terms of the related person transaction,
including the approximate dollar value of the amount involved in the transaction, and all the material facts as to the related person’s direct or indirect interest in, or relationship to, the related person transaction;
|
|
•
|
|
management must advise the Audit Committee as to whether the related person transaction complies with the terms of our agreements governing our material outstanding indebtedness that limit
or restrict our ability to enter into a related person transaction;
|
|
•
|
|
management must advise the Audit Committee as to whether the related person transaction will be required to be disclosed in our applicable filings under the Securities Act of 1933, as
amended (the “Securities Act”) or the Exchange Act, and related rules, and, to the extent required to be disclosed, management must ensure that the related person transaction is disclosed in accordance with such Acts and related rules; and
|
|
•
|
|
management must advise the Audit Committee as to whether the related person transaction constitutes a “personal loan” for purposes of Section 402 of the Sarbanes-Oxley Act of 2002.
|
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
Weighted Average
Exercise Price of Outstanding Options, Warrants and Rights |
Number of Securities
Remaining Available for Future Issuance Under Equity Compensation Plans |
||||||||||
Equity Compensation plans approved by security holders
|
5,000,000
|
*
|
59.95
|
2,516,498
|
†
|
|||||||
Equity Compensation plans not approved by security holders
|
-
|
-
|
||||||||||
Total
|
5,000,000
|
*
|
59.95
|
2,516,498
|
†
|
* |
Stock options, SARs and RSUs were issued pursuant to the 2012 Incentive Compensation Plan (the “2012 ICP”) and the 2018 Incentive Compensation Plan that was approved at the 2018 Annual Stockholders Meeting (the “2018 ICP”). Shares of our
Common Stock to be issued upon exercise of these equity awards are registered on our Registration Statement on Form S-8 covering 4,000,000 shares filed with the SEC on May 18, 2012 and our Registration Statement filed with the SEC on May 8,
2018 covering 5,000,000 shares.
|
† |
Following the approval at the 2018 Annual Meeting of Stockholders of our 2018 ICP no further awards will be granted under the 2012 ICP, though there are still unexercised options outstanding under the 2012 ICP.
|
This proxy is solicited on behalf of the Board of Directors of the Company.
This proxy, when properly executed, will be voted in accordance with the instructions given above. If no instructions are given, this proxy will be voted "FOR" the election of
each Director nominee and “FOR” proposals 2 and 3.
|
|
1.
|
Election of Directors.
|
|
|
|
FOR | AGAINST | ABSTAIN |
||||
|
|
(A) Isaac Angel
|
☐
|
☐
|
☐
|
|
|
|
(B) Albertus Bruggink
|
☐
|
☐
|
☐
|
|
|
|
(C) Dan Falk
|
☐
|
☐
|
☐
|
|
|
|
(D) David Granot
|
☐
|
☐
|
☐
|
|
(E) Mike Nikkel
|
☐ | ☐ |
☐ | |||
(F) Dafna Sharir
|
☐ | ☐ | ☐ | |||
|
|
(G) Stanley B. Stern
|
☐
|
☐
|
☐
|
|
|
|
|
(H) Hidetake Takahashi
|
☐
|
☐
|
☐
|
|
|
|
(I) Byron G. Wong
|
☐
|
☐
|
☐
|
2. |
To ratify the appointment of Kesselman Kesselman, a member firm of PricewaterhouseCoopers International Limited, as independent auditors of the Company for 2021.
|
☐ | ☐ | ☐ | ||
|
|
|
|
|
|
|
3. |
To approve, in a non-binding, advisory vote, the compensation of our named executive officers.
|
☐ | ☐ | ☐ |
||
|
|
|
|
|
|
|
To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not
be submitted via this method.
|
☐
|
Note: In their discretion, the
proxy holders are authorized to vote upon such other business as may properly come before the meeting or any adjustment or postponement thereof.
|
Signature of Stockholder
|
|
Date:
|
|
Signature of Stockholder
|
|
Date:
|
|
Note:
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney,
trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person.
|